Dr. Marisa Domingo-Calap is a Spanish researcher and the CEO of Evolving Therapeutics, a University of Valencia spin-off founded in 2023. The company specializes in developing bacteriophage-based solutions to combat multidrug-resistant bacteria affecting human, animal, and plant health. With a background in agricultural engineering, Dr. Domingo-Calap has led pioneering projects, including the first pilot application of phage therapy in agriculture in Spain. This initiative targets Xylella fastidiosa, a bacterial pathogen threatening various crops in the Balearic Islands. Under her leadership, Evolving Therapeutics has received significant recognition, including a €100,000 investment from Angels Capital, Juan Roig’s investment firm. This funding supports the expansion of the company’s laboratory and workforce, enhancing its capacity to innovate in the field of phage therapy. Dr. Domingo-Calap’s work exemplifies a commitment to advancing sustainable and effective solutions in the fight against antimicrobial resistance.